Lasmiditan

(Reyvow®)

Reyvow®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassSerotonin (5-HT) 1F receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 16 systematic review(s)/meta-analysis(es). [1-16]
  • Lasmiditan, particularly at a dose of 200 mg, was effective in achieving pain freedom at 2 hours post-dose and sustained pain freedom at 24 hours, although some studies indicated no significant difference between the 100 mg and 200 mg dosages for pain relief at 2 hours.
  • In comparison to triptans, lasmiditan was generally less effective in achieving pain freedom and pain relief at 2 hours; however, it demonstrated comparable efficacy to gepants such as rimegepant and ubrogepant while being associated with a higher incidence of adverse events.
  • Lasmiditan was effective for the acute treatment of menstrual migraine (MM), showing effectiveness similar to sumatriptan, with the 200 mg dose proving more effective than the 100 mg dose but also associated with a higher risk of adverse events.
  • Lasmiditan was associated with a high incidence of adverse events, particularly at the 200 mg dose, with common adverse effects including dizziness, somnolence, paresthesia, fatigue, and nausea; this higher dose also showed an increased risk of adverse events compared to the 100 mg dose.
  • Central nervous system-related adverse events, such as dizziness and somnolence, were the most frequently reported, while no significant cardiovascular-related adverse events were noted, which is relevant for patients with cardiovascular risks.
  • Lasmiditan was not specifically mentioned for preventive treatment in MM, which is addressed by frovatriptan and calcitonin gene-related peptide antibodies (CGRP) monoclonal antibodies (erenumab, galcanezumab).
  • The comparison of dosages indicated that lasmiditan 200 mg was generally more effective than 100 mg for achieving pain freedom at both 2 hours and 24 hours, although the higher dosage was also associated with a greater incidence of adverse events.

Product Monograph / Prescribing Information

Document TitleYearSource
Reyvow (lasmiditan) Prescribing Information.2022Lilly USA, LLC., Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis2024BMJ (Clinical Research Ed.)
Acute and preventive treatment of menstrual migraine: a meta-analysis2024The Journal of Headache and Pain
Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data2024Clinical Neuropharmacology
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials2024The Journal of Headache and Pain
Comparison of Lasmiditan 200 mg Versus 100 mg for Migraine Patients: A Meta-analysis of Randomized Controlled Studies2024Clinical Neuropharmacology
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature2023An International Journal of Headache
Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis2022Indian Journal of Pharmacology
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm2022The Clinical Journal of Pain
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings2022The Journal of Headache and Pain
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis2022Expert Review of Pharmacoeconomics & Outcomes Research
The Effect and Safety of 5-HT(1F) Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis2021BioMed Research International
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis2021JAMA Network Open
Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis2021Annals of Indian Academy of Neurology
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis2021The Journal of the American Medical Association
Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials2020CNS Drugs
Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis2020The Journal of Headache and Pain

Clinical Practice Guidelines